Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VQW-765 · 2 trials · 2 indications
Subjective Units of Distress Scale (SUDS) during performance phase, scored from 0-100 with a higher score indicating higher distress.
| Arm | Type | Description |
|---|---|---|
| VQW-765 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VQW-765 | DRUG | oral capsule |
| Placebo | DRUG | oral capsule |
Inclusion Criteria: 1. Ability and willingness to provide written informed consent. 2. Male and female subjects aged 18-65 years, inclusive. 3. Current diagnosis of social anxiety disorder. 4. Liebowitz Social Anxiety Scale total score ≥60. 5. Public Speaking Anxiety Scale total score ≥60. 6. Hamil...
VQW-765 is an investigational small molecule being developed for the on-demand treatment of Social Anxiety Disorder (SAD) and for Performance Anxiety. It is currently in clinical development, with a Phase 2 study completed for Performance Anxiety and a Phase 3 study for Social Anxiety Disorder.
VQW-765 targets the α7-nicotinic acetylcholine receptor (α7-nAChR). This receptor is a type of nicotinic acetylcholine receptor that is involved in the nervous system, and VQW-765 is designed to modulate its activity to address symptoms of anxiety.
VQW-765 is being developed by Vanda Pharmaceuticals Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol VNDA. Vanda is conducting clinical trials to evaluate the drug's safety and efficacy for anxiety-related conditions.
VQW-765 is in Phase 3 clinical development for Social Anxiety Disorder (SAD), based on a Phase 3 trial that is active but not recruiting. A Phase 2 study for Performance Anxiety has been completed. The drug is investigational and not yet approved by regulatory authorities.
VQW-765 has two clinical trials. NCT07221578 is a Phase 3 study evaluating the drug for on-demand treatment of Social Anxiety Disorder, with 500 participants, and is active but not recruiting. NCT04800237 is a completed Phase 2 study in Performance Anxiety with 230 participants. Both were conducted in the United States.
No, VQW-765 is a unique investigational compound developed by Vanda Pharmaceuticals. It is not known to be the same as any other marketed drug. It is being studied specifically for its effects on anxiety disorders through its action on the α7-nAChR receptor.